Amalgamated Bank Y M Abs Therapeutics, Inc. Transaction History

Amalgamated Bank

$12.1 Billion
Q3 2024

A detailed history of Amalgamated Bank transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 1,217 shares of YMAB stock, worth $9,918. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,217

Previous 1,217 -0.0%

Holding current value

$9,918

Previous $15,000 6.67%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 23, 2024	SELL	$6.57 - $18.69 $19,079 - $54,275	-2,904 Reduced 70.47%	1,217 $20,000
Q4 2023 Feb 06, 2024	SELL	$4.88 - $7.42 $1,766 - $2,686	-362 Reduced 8.07%	4,121 $28,000
Q2 2023 Aug 11, 2023	SELL	$5.68 - $10.34 $3,214 - $5,852	-566 Reduced 11.21%	4,483 $30,000
Q1 2023 May 02, 2023	SELL	$2.83 - $5.11 $2,179 - $3,934	-770 Reduced 13.23%	5,049 $25,000
Q3 2022 Nov 09, 2022	BUY	$13.96 - $19.67 $1,284 - $1,809	92 Added 1.61%	5,819 $84,000
Q2 2022 Aug 15, 2022	BUY	$8.22 - $15.13 $172 - $317	21 Added 0.37%	5,727 $87,000
Q1 2022 Jun 30, 2022	BUY	$6.55 - $17.42 $37,374 - $99,398	5,706 New	5,706 $68,000
Q3 2021 Oct 29, 2021	SELL	$27.47 - $37.31 $181,274 - $246,208	-6,599 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$25.45 - $37.64 $167,944 - $248,386	6,599 New	6,599 $223,000
Q1 2021 May 13, 2021	SELL	$29.16 - $51.96 $138,918 - $247,537	-4,764 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$37.86 - $54.26 $180,365 - $258,494	4,764 New	4,764 $235,000
Q3 2020 Oct 30, 2020	SELL	$35.13 - $43.62 $168,342 - $209,027	-4,792 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$23.66 - $49.53 $113,378 - $237,347	4,792 New	4,792 $207,000

Others Institutions Holding YMAB

# of Institutions

106

Shares Held

24.5M

Call Options Held

40.3K

Put Options Held

400

View Full List

About Y-mAbs Therapeutics, Inc.

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $356M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

More about YMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.

Account

Amalgamated Bank Y M Abs Therapeutics, Inc. Transaction History